KR20190134718A - 전립선암을 위한 병용 요법 - Google Patents

전립선암을 위한 병용 요법 Download PDF

Info

Publication number
KR20190134718A
KR20190134718A KR1020197032257A KR20197032257A KR20190134718A KR 20190134718 A KR20190134718 A KR 20190134718A KR 1020197032257 A KR1020197032257 A KR 1020197032257A KR 20197032257 A KR20197032257 A KR 20197032257A KR 20190134718 A KR20190134718 A KR 20190134718A
Authority
KR
South Korea
Prior art keywords
patient
prednisone
abiraterone acetate
administering
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197032257A
Other languages
English (en)
Korean (ko)
Inventor
마가렛 케이. 유
린다 앤 스나이더
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20190134718(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20190134718A publication Critical patent/KR20190134718A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
KR1020197032257A 2017-04-13 2018-04-09 전립선암을 위한 병용 요법 Ceased KR20190134718A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13
US62/485,164 2017-04-13
PCT/US2018/026661 WO2018191141A1 (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Publications (1)

Publication Number Publication Date
KR20190134718A true KR20190134718A (ko) 2019-12-04

Family

ID=62067858

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197032257A Ceased KR20190134718A (ko) 2017-04-13 2018-04-09 전립선암을 위한 병용 요법

Country Status (33)

Country Link
US (4) US20180296574A1 (enExample)
EP (3) EP3609497B1 (enExample)
JP (3) JP7141408B2 (enExample)
KR (1) KR20190134718A (enExample)
CN (2) CN110753545A (enExample)
AU (2) AU2018251594A1 (enExample)
CA (1) CA3059562A1 (enExample)
CL (1) CL2019002871A1 (enExample)
CO (1) CO2019011591A2 (enExample)
CR (1) CR20190467A (enExample)
DK (1) DK3609497T3 (enExample)
DO (1) DOP2019000264A (enExample)
EA (1) EA201992430A1 (enExample)
ES (1) ES2931052T3 (enExample)
HR (1) HRP20221327T1 (enExample)
HU (1) HUE060460T2 (enExample)
IL (2) IL269879B2 (enExample)
JO (1) JOP20190244A1 (enExample)
LT (1) LT3609497T (enExample)
MA (1) MA48728B1 (enExample)
MD (1) MD3609497T2 (enExample)
MX (2) MX2019012296A (enExample)
MY (1) MY209010A (enExample)
NI (1) NI201900105A (enExample)
PE (1) PE20200444A1 (enExample)
PH (1) PH12019502317A1 (enExample)
PL (1) PL3609497T3 (enExample)
PT (1) PT3609497T (enExample)
RS (1) RS63832B1 (enExample)
SG (1) SG11201909552VA (enExample)
SM (1) SMT202200467T1 (enExample)
UA (1) UA129514C2 (enExample)
WO (1) WO2018191141A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
WO2020139339A1 (en) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
WO2021224471A1 (en) * 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Pharmaceutical formulations of abiraterone acetate and niraparib
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
WO2023109758A1 (en) 2021-12-15 2023-06-22 Hunan Huize Biopharma S&T Co., Ltd Abiraterone acetate-containing composition and application thereof
AU2023250030A1 (en) * 2022-04-07 2024-11-07 Astrazeneca Ab Combination therapy for treating cancer
WO2024203348A1 (ja) * 2023-03-31 2024-10-03 ソニーグループ株式会社 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法
WO2025027138A1 (en) * 2023-08-02 2025-02-06 Janssen Pharmaceutica Nv Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62034B1 (sr) 2006-08-25 2021-07-30 Janssen Oncology Inc Kompozicije za lečenje raka
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
GEP20115337B (en) 2007-01-10 2011-11-25 St Di Ricerche Di Biologia Molecolare P Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
NZ586675A (en) 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (en) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use

Also Published As

Publication number Publication date
PT3609497T (pt) 2023-01-23
JP7141408B2 (ja) 2022-09-22
JP7407880B2 (ja) 2024-01-04
CL2019002871A1 (es) 2019-12-27
EP4176879A1 (en) 2023-05-10
EA201992430A1 (ru) 2020-02-28
IL269879B2 (en) 2025-10-01
PL3609497T3 (pl) 2023-01-23
EP3609497A1 (en) 2020-02-19
EP3609497B1 (en) 2022-10-12
LT3609497T (lt) 2022-12-12
PE20200444A1 (es) 2020-02-28
CN110753545A (zh) 2020-02-04
IL320452A (en) 2025-06-01
IL269879B1 (en) 2025-06-01
CO2019011591A2 (es) 2020-02-28
AU2024202346A1 (en) 2024-05-02
JP2024023344A (ja) 2024-02-21
US20240398837A1 (en) 2024-12-05
HRP20221327T1 (hr) 2023-03-17
MA48728A (fr) 2020-04-08
JOP20190244A1 (ar) 2019-10-13
DOP2019000264A (es) 2020-07-15
PH12019502317A1 (en) 2020-07-06
BR112019021466A2 (pt) 2020-05-12
DK3609497T3 (da) 2022-10-31
HUE060460T2 (hu) 2023-03-28
IL269879A (enExample) 2019-11-28
US20180296574A1 (en) 2018-10-18
MY209010A (en) 2025-06-16
WO2018191141A1 (en) 2018-10-18
CN119235874A (zh) 2025-01-03
JP2020516646A (ja) 2020-06-11
NI201900105A (es) 2020-03-11
SMT202200467T1 (it) 2023-01-13
SG11201909552VA (en) 2019-11-28
EP4176878A1 (en) 2023-05-10
ES2931052T3 (es) 2022-12-23
AU2018251594A1 (en) 2019-10-24
MD3609497T2 (ro) 2023-03-31
RS63832B1 (sr) 2023-01-31
CR20190467A (es) 2020-03-09
MX2019012296A (es) 2019-11-28
MX2023009569A (es) 2023-08-22
US20240245710A1 (en) 2024-07-25
UA129514C2 (uk) 2025-05-21
US20220175801A1 (en) 2022-06-09
MA48728B1 (fr) 2022-10-31
CA3059562A1 (en) 2018-10-18
JP2022141881A (ja) 2022-09-29

Similar Documents

Publication Publication Date Title
JP7407880B2 (ja) 前立腺癌の併用療法
Hoy Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer
JP2016515586A (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
JP2024510612A (ja) ソトラシブ投与レジメン
EP4340842B1 (en) Sotorasib for use in the treatment of cancer
JP2022518235A (ja) 進行期固形腫瘍がんの治療用ｒｎａ
HK40092155A (en) Combination therapy for prostate cancer
EA044835B1 (ru) Комбинированная терапия рака предстательной железы
BR112019021466B1 (pt) Composição compreendendo niraparibe, acetato de abiraterona, e prednisona, bem como uso dos referidos compostos
JP2008526773A (ja) ベクロメタゾンジプロピオネート及びプレドニゾンでの、移植片対宿主病及び白血病の治療
US20250268900A1 (en) Combination therapy using a substituted pyrimidin-4(3h)-one and nivolumab as well as its use in the treatment of cancer
Vicente-Baz et al. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort
Ruppert et al. GO41036: a Phase Ia/Ib open-label, multicenter study evaluating the safety and pharmacokinetics of tiragolumab in combination with atezolizumab and daratumumab in patients with R/R MM: P-270
EP4665725A2 (en) Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations
WO2024173931A2 (en) Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations
KR20240037954A (ko) 니라파립을 이용한 전이성 거세-저항성 전립선암의 치료
CN116981462A (zh) 索托拉西布给药方案
WO2021142237A1 (en) Methods for administering lucitanib and combinations thereof
Kollepara et al. Integrating Emerging Science into Clinical Practice: Targeting Androgen Signaling in Castration Resistant Metastatic Prostate Cancer
Kübier et al. 7046 POSTER Final Analysis of a Phase l/lla Study With CV9103, an Intradermally Administered Prostate Cancer Immunotherapy Based on Self Adjuvanted mRNA

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601